{
  "abstract": "Modern cancer diagnostics is heavily reliant on molecular data. Next-generation sequencing using liquid biopsy (LB) is primarily focused on identifying predictive and prognostic biomarkers to guide systemic therapy decision making. However, additional findings including genomic variants of possible or probable germline origin are detected in a significant minority of patients (3%-18%), with significant implications for patients and their families. Pretest information provision regarding both the purpose and potential benefits of the test and additional findings on LB varies in clinical practice, with little guidance for clinicians regarding the degree of detail required regarding possible additional findings. LB requires explicit disclosure of these aspects. Implementing a standardized, context-dependent approach to this discussion, with nationally standardized information provision tools, should be prioritized to enable patient-centered decision making regarding LB, without prioritizing the incidentalome over the primary purpose of the test-refining and optimizing treatment options.",
  "abstract_shown": true,
  "affiliations": [
    "Royal Marsden Hospital, London, United Kingdom.",
    "Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Manchester, United Kingdom.",
    "Manchester Cancer Genomic Medicine, North West Genomic Laboratory Hub, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.",
    "School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.",
    "NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.",
    "The Institute of Cancer Research, London, United Kingdom.",
    "Clinical Genetics, 7(th) Floor Borough Wing, Guy's Hospital, London, United Kingdom.",
    "South West Thames Regional Genomics Service, London, United Kingdom.",
    "The Christie NHS Foundation Trust, Manchester, United Kingdom.",
    "Department of Pathology, St Vincent's University Hospital, Dublin 4, Ireland.",
    "Nuffield Department of Medicine, Centre for Personalised Medicine, University of Oxford, Oxford, United Kingdom.",
    "Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.",
    "Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.",
    "Newcastle University, Newcastle Upon Tyne, United Kingdom."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 15,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "David John McMahon",
      "orcid": "0000-0001-5827-3464"
    },
    {
      "affs": [
        0
      ],
      "name": "Elizabeth Bancroft"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "George J Burghel",
      "orcid": "0000-0001-9360-8194"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Ellen Copson",
      "orcid": "0000-0001-8994-4056"
    },
    {
      "affs": [
        0,
        5
      ],
      "name": "Michael Hubank",
      "orcid": "0000-0002-2901-0742"
    },
    {
      "affs": [
        0
      ],
      "name": "Jennifer Wiggins"
    },
    {
      "affs": [
        6,
        7
      ],
      "name": "Katie Snape",
      "orcid": "0000-0002-1739-7986"
    },
    {
      "affs": [
        1,
        8
      ],
      "name": "Natalie Cook",
      "orcid": "0000-0003-2606-1082"
    },
    {
      "affs": [
        9
      ],
      "name": "Ian Frayling"
    },
    {
      "affs": [
        10,
        11
      ],
      "name": "Matthew J Murray",
      "orcid": "0000-0002-4480-1147"
    },
    {
      "affs": [
        12,
        13
      ],
      "name": "Alastair Greystoke",
      "orcid": "0000-0001-9168-0387"
    },
    {
      "affs": [
        1,
        8
      ],
      "name": "Matthew G Krebs",
      "orcid": "0000-0001-7540-3064"
    },
    {
      "affs": [
        0,
        5
      ],
      "name": "Sanjay Popat",
      "orcid": "0000-0003-2087-4963"
    },
    {
      "affs": [
        0,
        5
      ],
      "name": "Terri Patricia McVeigh"
    },
    {
      "name": "UK Circulating Biomarkers Network of Excellence and the National ctDNA Steering Committee"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e5cn7tjgnbmb0.bib",
  "cited_by": 0,
  "doi": "10.1200/po-26-00366",
  "fulltext_url": "https://europepmc.org/articles/PMC13668035",
  "id": "e5cn7tjgnbmb0",
  "issns": [
    "2473-4284"
  ],
  "landing_url": "https://europepmc.org/article/MED/42842845",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "1311|BRCA gene mutations in cancer"
    ]
  ],
  "openalex": "W7220843614",
  "pdf_url": "https://europepmc.org/articles/PMC13668035?pdf=render",
  "pmcid": "PMC13668035",
  "pmid": "42842845",
  "published": "2026-10-07",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/e5cn7tjgnbmb0.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:02Z",
      "native_id": "MED:42842845",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42842845"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:1311|BRCA gene mutations in cancer",
      "subfield": "genetics-genomics"
    }
  ],
  "title": "Genomic Analysis Using Liquid Biopsy: Considerations for Pretest Counseling in UK Practice.",
  "title_text": "Genomic Analysis Using Liquid Biopsy: Considerations for Pretest Counseling in UK Practice.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:02Z",
  "url": "https://research.draconitic.com/paper/e5cn7tjgnbmb0",
  "venue": "JCO precision oncology",
  "versions": []
}